Hormone-refractory prostate cancer+1
RecruitingStudy Comparing Ifinatamab Deruxtecan and Docetaxel for Patients with Advanced Prostate Cancer Resistant to Hormone Therapy
Study Comparing Ifinatamab Deruxtecan and Docetaxel for Patients with Advanced Prostate Cancer Resistant to Hormone Therapy
- Disease:Hormone-refractory prostate cancerProstate cancer metastatic
- Substances:Codeine PhosphateDocetaxel+5
Italy- Participants:18–64 years · 65+ years
- Substances:Codeine Phosphate
- Sponsor:Merck Sharp & Dohme LLC










